← 483 OBSERVATION EXPLORER

FDA 483 OBSERVATION · #155 OF 1,000 MOST-CITED

Quality Audit/Reaudit - conducted

FDA cited this observation 152 times across 147 firms in recent inspections. Below: how it breaks down by program area and fiscal year, and real examples of how FDA worded it on Form FDA 483.

BY PROGRAM AREA
Devices152
BY FISCAL YEAR
FY202611
FY202525
FY202411
FY202328
FY202216
FY20215
FY202011
FY201919
FY201817
FY20179

What this observation is associated with

Firms cited for this observation also appear in FDA compliance actions — warning letters, injunctions, or seizures — at 1.5× the rate of the average FDA-cited firm (12.9% vs 8.3%), across 147 FEI-matched firms.

This is an association, not causation, and reflects co-occurrence in FDA's records — not a claim that the observation caused or preceded the action.

CHECKING ACCESS

Checking your Professional access…

How FDA worded it — real examples

Quality audits have not been performed.

Pleural Dynamics, Inc. · Minnetonka, Minnesota · Devices · 2026-01-13

Quality audits have not been performed.

Encore Laboratory · Santa Ana, California · Devices · 2026-01-09

Quality audits and reaudits have not been performed.

NeuroCareAI, Inc. · Prosper, Texas · Devices · 2025-12-12

Quality audits have not been performed.

Hensler Surgical Products, LLC · Wilmington, North Carolina · Devices · 2025-12-11

Quality audits have not been performed.

Mid Central Medical, LLC. · Saint Vincent, Minnesota · Devices · 2025-12-09

Quality audits have not been performed.

Cryo-Dynamics, Inc. · Southlake, Texas · Devices · 2025-12-04

Related SPEQ references

Where to read the requirements behind this observation area on SPEQ. These are SPEQ's topic and audience pages — not an FDA classification of the citation.

Medical devices

Examples are a representative sample of FDA's published inspection observations. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →